The Potential Role of Platelet - rich Plasma in the Treatment of Melasma
DOI:
https://doi.org/10.61841/4dvkvr66Keywords:
PRP, Modified Melasma Area and Severity Index, mMASI ScoreAbstract
Objective: To evaluate the response of patients with melasma to intradermal injection of platelet-rich plasma. Background: Melasma is a frequently acquired disorder of hyperpigmentation that is characterized by asymptomatic light to dark brown patches on the face involving the forehead, cheeks, chin, and upper lip. In spite of several treatments for melasma, such as topical agents, chemical-based peeling, and laser and light source therapies, the treatment results are variable, with complications such as irritation, post-inflammatory hyperpigmentation, or hypopigmentation. Nonetheless, platelet-rich plasma (PRP) is getting attention in aesthetic medicine because of its autologous nature and mild side effects compared to other melasma treatments. Methods: The present study included 30 patients with melasma having Fitzpatrick skin types III and IV. The duration of the study extended from February to November 2019. The therapeutic course consisted of 5 sessions of platelet-rich plasma (PRP) injections with an interval of 2 weeks between them. PRP was prepared by using a double-spin method and then activated with calcium chloride. The final evaluation was analyzed by percent of reduction in baseline of mMASI score. It's considered a mild response when the reduction of the baseline mMASI was between 0 and 25%; a 25-50% reduction is considered a fair response; a 50-75% reduction is considered a good response; and >75% is considered an excellent response. The treatment trial was considered effective if there was a reduction in the mMASI score from the baseline that was greater than 50%. Results: Of 30 enrolled patients, 5 (16.7%) patients showed good response, 19 (63.3%) patients showed fair response, and 6 (20%) patients showed poor response. None of the patients showed an excellent response. The overall efficacy of treatment was 16.7%. Conclusion: PRP appears to be a promising adjuvant therapy for recalcitrant cases of melasma.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.